Pharmiweb ChannelsAll | PharmaCo | Clinical Research | R&D/BioTech | Sales/Mktg | Healthcare | Recruitment | Pharmacy | Medical Comms RSS Feed RSS Feeds


Press Release

Epizyme to Participate in Oppenheimer & Co. 28th Annual Healthcare Conference

Posted on: 12 Mar 18

CAMBRIDGE, Mass., March 12, 2018 (GLOBE NEWSWIRE) -- Epizyme, Inc. (NASDAQ:EPZM), a clinical-stage biopharmaceutical company creating novel epigenetic therapies, today announced that management will present at the Oppenheimer & Co. 28th Annual Healthcare Conference at 10:20 a.m. ET on March 20, 2018 in New York City.

To access the live webcast of Epizyme’s presentation, please visit the Events & Presentations page within the Investor section of the company’s website at A replay of the webcast will be available on the Epizyme website for 60 days following the event.

About Epizyme, Inc.
Epizyme, Inc. is a clinical-stage biopharmaceutical company committed to rewriting treatment for cancer and other serious diseases through novel epigenetic medicines. Epizyme is broadly developing its lead product candidate, tazemetostat, a first-in-class EZH2 inhibitor, with studies underway in both solid tumors and hematological malignancies, as a monotherapy and combination therapy in relapsed and front-line disease. The company is also developing a novel G9a program and its next development candidate, EZM8266, is targeting sickle cell disease. By focusing on the genetic drivers of disease, Epizyme's science seeks to match targeted medicines with the patients who need them. For more information, visit


Cheya Pope, Epizyme, Inc.
(617) 229-7561

Jason Fredette, Epizyme, Inc.  
(617) 500-0623



Last updated on: 12/03/2018

Site Map | Privacy & Security | Cookies | Terms and Conditions is Europe's leading industry-sponsored portal for the Pharmaceutical sector, providing the latest jobs, news, features and events listings.
The information provided on is designed to support, not replace, the relationship that exists between a patient/site visitor and his/her physician.